Immune Thrombocytopenia (ITP) Market Research Report: Information By Treatment (Intravenous Immunoglobulins, Corticosteroids, Thrombopoietin Receptor Agonists, and Others), By End-user (Hospitals and Clinics, Specialty Centers, Research and Academic Institutes, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

1 Report Prologue

2 Executive Summary

3 Introduction

3.1 Definition 18

3.2 Scope of the Study 18

3.3 List of Assumptions 19

3.4 Market Structure 19

4 Research Methodology

4.1 Research Process 21

4.2 Primary Research 22

4.3 Secondary Research 23

4.4 Market Size Estimation 23

4.5 Forecast Model 24

5 Market Dynamics

5.1 Overview 26

5.2 Drivers 27

5.2.1 Rising prevalence of Immune Thrombocytopenia (ITP) 27

5.2.2 Growing financial support by various private and government organizations 27

5.3 Restraints 27

5.3.1 Side effects of treatment options 27

5.3.2 High cost of IVIG treatment 28

5.4 Opportunities 28

5.4.1 Emerging therapies in immune thrombocytopenia 28

6 Market Factor Analysis

6.1 Value chain analysis 30

6.1.1 R&D and Designing 30

6.1.2 Manufacturing 30

6.1.3 Distribution & Sales 30

6.1.4 Post-Sales Monitoring 30

6.2 Porter’s Five Forces Model 31

6.2.1 Bargaining Power of Suppliers 32

6.2.2 Bargaining Power of Buyers 32

6.2.3 Threat of New Entrants 32

6.2.4 Threat of Substitutes 32

6.2.5 Intense Rivalry 32

7 Global Immune Thrombocytopenia (ITP) Market by Type

7.1 Overview 34

7.2 Acute Immune Thrombocytopenia 35

7.3 Chronic Immune Thrombocytopenia 35

8 Global Immune Thrombocytopenia (ITP) Market by Treatment

8.1 Overview 37

8.2 Corticosteroids 38

8.3 Thrombopoietin receptor agonists 38

8.4 Intravenous Immunoglobulins (IVIG) 39

9 Global Immune Thrombocytopenia (ITP) Market by End-user

9.1 Overview 41

9.2 Hospital & Clinics 42

9.3 Specialty Centers 42

9.4 Research and Academic Institutes 43

10 Global Immune Thrombocytopenia (ITP) Market by Region

10.1 Overview 45

10.2 Americas 47

10.2.1 North America 48

10.2.1.1 US 50

10.2.1.2 Canada 51

10.2.2 South America 52

10.3 Europe 54

10.3.1 Western Europe 55

10.3.1.1 Germany 57

10.3.1.2 France 58

10.3.1.3 UK 59

10.3.1.4 Italy 60

10.3.1.5 Spain 61

10.3.1.6 Rest of Western Europe 62

10.3.2 Eastern Europe 63

10.4 Asia-Pacific 65

10.4.1 Japan 66

10.4.2 China 67

10.4.3 India 68

10.4.4 South Korea 69

10.4.5 Australia 71

10.4.6 Rest of Asia-Pacific 72

10.5 Middle East & Africa 73

10.5.1 Middle East 74

10.5.2 Africa 75

11 Competitive Landscape

11.1 Overview 78

11.2 Company Share Analysis 78

12 Company Profiles

12.1 Amgen Inc. 80

12.1.1 Company Overview 80

12.1.2 Financial Overview 80

12.1.3 Products/Services Offered 81

12.1.4 Key Developments 81

12.1.5 SWOT Analysis 81

12.1.6 Key Strategy 81

12.2 CSL Limited 82

12.2.1 Financial Overview 82

12.2.2 Products/Services Offered 82

12.2.3 Key Developments 82

12.2.4 SWOT Analysis 83

12.2.5 Key Strategy 83

12.3 Dova Pharmaceuticals 84

12.3.1 Company Overview 84

12.3.2 Financial Overview 84

12.3.3 Products/Services Offered 84

12.3.4 Key Developments 84

12.3.5 SWOT Analysis 85

12.3.6 Key Strategy 85

12.4 F. Hoffmann-La Roche Ltd 86

12.4.1 Company Overview 86

12.4.2 Financial Overview 86

12.4.3 Products/Services Offered 86

12.4.4 Key Developments 87

12.4.5 SWOT Analysis 87

12.4.6 Key Strategy 87

12.5 Jiangsu Hengrui Pharmaceutical Co., Ltd. 88

12.5.1 Company Overview 88

12.5.2 Financial Overview 88

12.5.3 Products/Services Offered 88

12.5.4 SWOT Analysis 88

12.5.5 Key Developments 89

12.5.6 Key strategy 89

12.6 Kyowa Hakko Kirin Co., Ltd. 90

12.6.1 Company Overview 90

12.6.2 Financial Overview 90

12.6.3 Products/Services Offered 91

12.6.4 Key Developments 91

12.6.5 SWOT Analysis 91

12.6.6 Key Strategy 91

12.7 Ligand Pharmaceuticals, Inc. 92

12.7.1 Company Overview 92

12.7.2 Financial Overview 92

12.7.3 Products/Services Offered 92

12.7.4 Key Developments 93

12.7.5 SWOT Analysis 93

12.7.6 Key Strategy 93

12.8 Novartis AG 94

12.8.1 Company Overview 94

12.8.2 Financial Overview 94

12.8.3 Products/Services Offered 94

12.8.4 Key Developments 95

12.8.5 SWOT Analysis 95

12.8.6 Key Strategy 95

12.9 Rigel Pharmaceuticals, Inc. 96

12.9.1 Company Overview 96

12.9.2 Financial Overview 96

12.9.3 Products/Services Offered 96

12.9.4 Key Developments 97

12.9.5 SWOT Analysis 97

12.9.6 Key Strategy 97

12.10 Shire 98

12.10.1 Company Overview 98

12.10.2 Financial Overview 98

12.10.3 Products/Services Offered 99

12.10.4 Key Developments 99

12.10.5 SWOT Analysis 99

12.10.6 Key Strategy 99

12.11 Shionogi Inc. 100

12.11.1 Company Overview 100

12.11.2 Financial Overview 100

12.11.3 Products/Services Offered 101

12.11.4 Key Developments 101

12.11.5 SWOT Analysis 101

12.11.6 Key Strategy 101

13 Appendix

13.1 Discussion Blue Print 103

14 List of Tables

TABLE 1 MARKET SYNOPSIS 16

TABLE 2 LIST OF ASSUMPTIONS 19

TABLE 3 PRIMARY INTERVIEWS 21

TABLE 4 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 34

TABLE 5 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR ACUTE ITP BY REGION, 2027 TO 2032 (USD MILLION) 35

TABLE 6 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR CHRONIC ITP BY REGION, 2027 TO 2032 (USD MILLION) 35

TABLE 7 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 38

TABLE 8 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR CORTICOSTEROIDS BY REGION, 2027 TO 2032 (USD MILLION) 38

TABLE 9 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR THROMBOPOIETIN RECEPTOR AGONISTS BY REGION, 2027 TO 2032

(USD MILLION) 38

TABLE 10 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR INTRAVENOUS IMMUNOGLOBULINS (IVIG) BY REGION, 2027 TO 2032 (USD MILLION) 39

TABLE 11 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 41

TABLE 12 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR HOSPITAL & CLINICS BY REGION, 2027 TO 2032 (USD MILLION) 42

TABLE 13 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR SPECIALTY CENTERS BY REGION, 2027 TO 2032 (USD MILLION) 42

TABLE 14 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR RESEARCH AND ACADEMIC INSTITUTES BY REGION, 2027 TO 2032

(USD MILLION) 43

TABLE 15 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2027 TO 2032 (USD MILLION) 46

TABLE 16 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2027 TO 2032 (USD MILLION) 47

TABLE 17 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 47

TABLE 18 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 48

TABLE 19 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 48

TABLE 20 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2027 TO 2032 (USD MILLION) 49

TABLE 21 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 49

TABLE 22 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 49

TABLE 23 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 50

TABLE 24 US IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 50

TABLE 25 US IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 50

TABLE 26 US IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 51

TABLE 27 CANADA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 51

TABLE 28 CANADA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 51

TABLE 29 CANADA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 52

TABLE 30 SOUTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 52

TABLE 31 SOUTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 52

TABLE 32 SOUTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 53

TABLE 33 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2027 TO 2032 (USD MILLION) 54

TABLE 34 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 54

TABLE 35 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 55

TABLE 36 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 55

TABLE 37 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2027 TO 2032 (USD MILLION) 56

TABLE 38 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 56

TABLE 39 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 56

TABLE 40 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 57

TABLE 41 GERMANY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 57

TABLE 42 GERMANY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 57

TABLE 43 GERMANY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 58

TABLE 44 FRANCE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 58

TABLE 45 FRANCE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 58

TABLE 46 FRANCE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 59

TABLE 47 UK IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 59

TABLE 48 UK IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 59

TABLE 49 UK IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 60

TABLE 50 ITALY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 60

TABLE 51 ITALY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 60

TABLE 52 ITALY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 61

TABLE 53 SPAIN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 61

TABLE 54 SPAIN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 61

TABLE 55 SPAIN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 62

TABLE 56 REST OF WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 62

TABLE 57 REST OF WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 62

TABLE 58 REST OF WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 63

TABLE 59 EASTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 63

TABLE 60 EASTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 63

TABLE 61 EASTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 64

TABLE 62 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2027 TO 2032 (USD MILLION) 65

TABLE 63 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 65

TABLE 64 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 66

TABLE 65 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 66

TABLE 66 JAPAN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 66

TABLE 67 JAPAN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 67

TABLE 68 JAPAN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 67

TABLE 69 CHINA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 67

TABLE 70 CHINA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 68

TABLE 71 CHINA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 68

TABLE 72 INDIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 68

TABLE 73 INDIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 69

TABLE 74 INDIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 69

TABLE 75 SOUTH KOREA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 69

TABLE 76 SOUTH KOREA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 70

TABLE 77 SOUTH KOREA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 70

TABLE 78 AUSTRALIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 71

TABLE 79 AUSTRALIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 71

TABLE 80 AUSTRALIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 71

TABLE 81 REST OF ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 72

TABLE 82 REST OF ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 72

TABLE 83 REST OF ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 72

TABLE 84 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2027 TO 2032 (USD MILLION) 73

TABLE 85 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 73

TABLE 86 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 74

TABLE 87 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 74

TABLE 88 MIDDLE EAST IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 74

TABLE 89 MIDDLE EAST IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 75

TABLE 90 MIDDLE EAST IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 75

TABLE 91 AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 TO 2032 (USD MILLION) 75

TABLE 92 AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 TO 2032 (USD MILLION) 76

TABLE 93 AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 TO 2032 (USD MILLION) 76

15 List of Figures

FIGURE 1 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET: MARKET STRUCTURE 19

FIGURE 2 RESEARCH PROCESS 21

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 24

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET 26

FIGURE 5 VALUE CHAIN: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET 30

FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET 31

FIGURE 7 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2027 & 2032 (USD MILLION) 34

FIGURE 8 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2027 & 2032 (USD MILLION) 37

FIGURE 9 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2027 & 2032 (USD MILLION) 41

FIGURE 10 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2027 & 2032 (USD MILLION) 46

FIGURE 11 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2027 (%) 47

FIGURE 12 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2027 (%) 48

FIGURE 13 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2027 (%) 54

FIGURE 14 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2027 (%) 55

FIGURE 15 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2027 (%) 65

FIGURE 16 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2027 (%) 73

FIGURE 17 COMPANY SHARE ANALYSIS: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET, 2027 (%) 78